7 Pharma Stocks to Avoid at All Costs in 2019

7 Pharma Stocks to Avoid at All CostsPosted on Monday, November 26th, 2018 by Chris Markoch

The pharmaceutical sector has been on a roller coaster ride over the last several years. As recently as 2016, the industry was getting pinched by the double whammy of pressure to reduce drug costs and a corporate tax structure that was choking off topline growth. In the last year, many of the pharmaceutical companies have seen their stocks go through the roof as a result of the new tax policy. But not every pharmaceutical stock is showing strength.

Make no mistake, this is an industry that every investor – and every consumer – should want to see succeed. These companies are continuously introducing new drugs and treatments for cancer, Alzheimer’s, diabetes, and multiple sclerosis just to name a few. And that’s not to mention the drugs that help us manage our cholesterol, high blood pressure, and depression.

Not to mention, the baby boomer generation continues to reach retirement age. In 2018 alone, over three million people will be reaching retirement age and that pace isn’t expected to slow down significantly until 2029. As the number of retirees expands so too will their need for the products and services that come from this industry.

It’s expensive to develop these drugs, not to mention that it can take years for some of these products to reach the market. Our desire to want to believe in these treatments can allow investors to mistake an inflated valuation for a poor valuation.

But as an investor, we have to perform our due diligence, and there are some stocks that have qualitative or quantitative factors working against them. While the pharmaceutical is always changing, we’re providing a list of seven stocks that, for now, should stay out of your portfolio.

#1 - Eli Lilly and Co. (NYSE:LLY)

Eli Lilly And Co logo

Eli Lilly and Co. (NYSE: LLY) - Eli Lilly is in that space where they have a lot of products in development – and many are showing enormous promise, but the stock has been struggling with declining revenues since a series of patents expired in 2011. One of their newer drugs, Solanezumab, an Alzheimer’s drug, failed to produce the expected results. However, the company is resting a lot of their hope on two of their newest cancer drugs Cyramza and Portrazza, which have been approved but are not yet at the point where they are generating tangible revenue for the company. The company also recently suffered a setback when a court ruled against their appeal of a $20 million patent lawsuit in which the company was accused of infringing on a German patent with its Cialis product.

From a technical standpoint, the stock has an earnings per share (EPS) of 2.27 which is down -37% for the year. This has brought their EPS forecast for next year to 3.87%. And the P/E multiple for the stock is around 43 which is above its multiple of 33 two years ago that was considered high at that time. However, the performance of the stock year-to-date is 30.01%. What seems to be of more concern for investors is that Eli Lilly seems to be accepting its underperformance instead of aggressively combating it.



About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as migraine prevention. In addition, it offers immunology products for the treatment of adults with rheumatoid arthritis, as well as for the treatment of plaque psoriasis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia, and acute coronary syndrome. Further, the company provides animal health products, such as cattle feed additives; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and enteric diseases in swine and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; Nektar Therapeutics; NextCure, Inc.; Dicerna Pharmaceuticals; and AC Immune SA. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Current Price: $116.01
Consensus Rating: Buy
Ratings Breakdown: 10 Buy Ratings, 10 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $117.5467 (1.3% Upside)

#2 - GW Pharma (NASDAQ:GWPH)

GW Pharmaceuticals PLC- logo

GW Pharma (NASDAQ: GWPH) - GW Pharma had a big moment this summer when it received historical approval for Epidiolex, a pharmaceutical that is the first of its kind to be derived from cannabis. But since then the company has failed to sustain the momentum that pushed its stock up to its all-time high shortly before the launch. The stock is up just 2% for the year and is lagging behind others in the sector. If this was a short-term problem it would be one thing. However, in the last three years, the stock has consistently lagged behind the performance of the S&P Biotech ETF which has returned approximately 35%.

One of the reasons for the stock’s lackluster performance is a case of irrational expectations. The stock rose rapidly from $9 to $111 after its initial public offering (IPO) which may have created expectations the stock could not sustain. Although Epidiolex received approval in a very short timeframe, some analysts suggest it could have been shorter, and more importantly, the drug is experiencing some headwinds regarding pending competition from Zogenix and a question of whether major insurance companies will get behind the new drug. GW Pharma is a stock with a lot of potential, but right now it may be wise to wait until the picture gets clearer.



About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Current Price: $175.05
Consensus Rating: Buy
Ratings Breakdown: 10 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $206.7778 (18.1% Upside)

#3 - Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logo

Gilead Sciences (NASDAQ: GILD) - Gilead has had some big missteps in the past few years. For starters, they started seeing sales of their Hepatitis C products decline as far back as 2015. While some companies would respond to this by seeking out new sources of revenue, Gilead looked at what they perceived to be the high valuations across their industry and chose instead to take their pile of cash and put billions into a shareholder-rewards program. Things got worse when, at the beginning of 2018, new Hep C drugs came onto the market which has put further downward pressure on Gilead’s sales. In response to this, Gilead made what some analysts consider to be a curious acquisition of Kite Pharma which does not seem to provide them with competitive protection, nor will it provide them with an easy remedy for their declining top-line which is leading some analysts to question the opportunity cost. Kite Pharma specialized in adoptive-cell therapy which will be new to Gilead’s portfolio. This makes it hard to see Gilead becoming a leader in this space.



About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Current Price: $66.36
Consensus Rating: Buy
Ratings Breakdown: 14 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $82.3529 (24.1% Upside)

#4 - Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals (NASDAQ: ALNY) - The Cambridge, Massachusetts biotech firm specializes in creating techniques that can help block out the effects of harmful genes. Its initial application to showcase its techniques will be in the treatment of amyloidosis with a drug called Onpattro. If the company succeeds, they may become a very intriguing play, but right now the company is still working through a valuation problem. In 2017, the company’s $89.9 million revenue was largely the result of payments made from potential partners. However, Alynlam’s market value is $12.2 billion – that’s a pretty staggering 125 times revenue. The stock has risen from $42 in late 2016 to a 52-week high of around $123. The stock is down considerably from that point and is currently trading around $67. However, in their last earnings report, they showed an 87.9% decline in year-over-year revenue. Two reasons for this are value-based agreements (VBA) that make it less clear how much revenue their new drug will bring in. Particularly since it's impossible to predict how effective Onpattro may be. Further clouding the picture is that the FDA nixed the company's ability to market potential cardiac benefits of the drug which further clouds the picture of how Onpattro will fare against its competition.



About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Current Price: $67.54
Consensus Rating: Buy
Ratings Breakdown: 14 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $130.2353 (92.8% Upside)

#5 - Bluebird Bio (NASDAQ:BLUE)

bluebird bio logo

Bluebird Bio (NASDAQ: BLUE) - Another Cambridge, Massachusetts makes the list. Like Alnylam, Bluebird specializes in the area of gene therapy. In the case of Bluebird, they are focusing on applications for neurological disorders. The problem that investors are mulling over with Bluebird is the competitive landscape around its most promising drugs. In the pharmaceutical space, the window of exclusivity is very narrow and the space for Bluebird continues to be very crowded. Having said that, Bluebird also has valuation concerns. Their 2017 revenue was just under $40 million however its market value was $10.5 billion for a price/revenue ratio of 272. After the stock reached a record high of $236.17 in March of 2018, it has steadily retreated and is now selling around $119. The stock still has a market cap of $6.51 billion. If investors are looking for a positive sign, it's that Bluebird's pipeline is loaded. If only a few of these drugs take off, it could make the stock a buying opportunity. However, for now, the better play may be to let this one fly away.



About bluebird bio
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; and TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Current Price: $128.34
Consensus Rating: Buy
Ratings Breakdown: 12 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $167.0607 (30.2% Upside)

#6 - Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals logo

Adamas Pharmaceuticals (NASDAQ: ADMS) - Adamas has an approved Alzheimer’s drug in the market, Namenda, that has started to generate revenue for the company. In 2017, the drug’s revenue was less than $1 million. The drug is designed to treat Alzheimer’s related dementia. While analysts are estimating revenue from the drug could rise to $92 million in the next two years, it seems that investors were overly generous in their valuation of the company driving it up as high as $868 million. That’s a price/revenue ratio of 9 times estimates two years out. Investors though seem to be more concerned about their recently introduced Parkinson’s drug, Gocovri. They are questioning the commercial prospects for the drug which is entering a very competitive space with Osmolex. While there is a reason to believe Gocovri may prove to have a competitive advantage that will allow Adamas to be a big winner, there is a lot of uncertainty that seems to be manifesting itself in 2018. The stock has come back down to earth this year, falling from a high of $44 per share in early 2018 to its current price of right around $11.



About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Current Price: $5.73
Consensus Rating: Hold
Ratings Breakdown: 4 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $22.2857 (288.9% Upside)

#7 - Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics logo

Nektar Therapeutics (NASDAQ: NKTR) - The company continues to struggle with its latest cancer drug, NKTR-214. The combination treatment helped the stock soar in early 2018 when Bristol-Myers Squibb agreed to license rights to NKTR-214. However, after reaching that height, investors have become less than enthused about the drug's potential. The response rate with declined for both melanoma patients and kidney cancer patients. Why is this important? If the numbers don’t improve, the stock may not receive FDA approval.  What may be even more concerning is that the company withheld objective response rate (ORR) data for up to 69% of dosed patients. One of the primary rules of biotechnology is that a company does not withhold data unless it’s bad. The stock has fallen to around $37 per share from a lofty high of around $111. Until investors get more firm data over a series of reports, Nektar seems like one stock that should be avoided.



About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA and Pfizer Inc to develop a therapy for treating pancreatic cancer. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.

Current Price: $32.02
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $72.60 (126.7% Upside)

Investing in pharmaceutical stocks is not for the faint of heart. In addition to understanding the technical data that underpins every stock, investors are charged with understanding the science behind the stock. This can be difficult because it’s hard to not want to believe in these stocks. Because beyond the hope they provide for diseases that many families have been affected by such as cancer, Alzheimer’s, and multiple sclerosis, can cause these stocks to attract investor money as they see a growing market for these drugs as the world’s population continues to age.

But it’s important for investors to take the emotion out of these stocks. Because the drugs still have a high failure rate. When they fail, the decline in a company’s stock price can be disastrous. Many of the stocks in this report are down more than 50% from record highs just recorded this year.

These seven pharma stocks may have better days ahead of them, but for now, investors may want to take a pass.



More on MarketBeat
8 Fast-Growing Stocks You Should Own Right Now8 Fast-Growing Stocks You Should Own Right Now
Analysts Hate These 12 StocksAnalysts Hate These 12 Stocks
7 Heavily Discounted Stocks to Buy Today7 Heavily Discounted Stocks to Buy Today
15 Stocks that Insiders Love15 Stocks that Insiders Love
8 Low P/E Stocks with Room to Grow 8 Low P/E Stocks with Room to Grow
13 Stocks Institutional Investors Won13 Stocks Institutional Investors Won't Stop Buying
8 Stocks to Sell Before the New Year8 Stocks to Sell Before the New Year





Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel